SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Stellar is an open-source, decentralized network co-founded in 2014 by Jed McCaleb and Joyce Kim to facilitate the fast and low-cost transfer of value across different currencies and assets globally. Managed by the non-profit Stellar Development Foundation, the project serves as a global infrastructure that connects banks, payment systems, and individuals to expand financial access to underserved populations. Its main value proposition lies in providing a bridge between traditional money and digital networks through the use of Anchors, which are trusted entities that hold deposits and issue credits on the ledger.  The network operates using the Stellar Consensus Protocol and a Federated Byzantine Agreement, where nodes choose trusted sets of other nodes to agree on the state of the ledger. This system ensures high throughput and fast finality, where transactions are considered permanent and irreversible within seconds. Key features include a built-in distributed exchange for trading assets without intermediaries and the Soroban platform for developing smart contracts. Users can also utilize the network for tokenizing real-world assets or accessing decentralized finance services like peer-to-peer lending.  Stellar's native token, XLM, is essential for maintaining network integrity by acting as an intermediary to find efficient exchange paths and preventing spam through small transaction fees and minimum account balance requirements. Unlike many other digital assets, the network has no inflation because the community voted to disable the automatic creation of new tokens. While the project received early funding from the payments company Stripe, it is now sustained by a global community of validators and developers rather than traditional venture capital.

Stellar Lumens

Stellar Lumens is trending due to a major institutional partnership with the DTCC, which plans to integrate tokenized assets like U.S. Treasuries and ETFs onto the Stellar network. The community is buzzing with excitement over this move into real-world asset tokenization, fueling a massive short squeeze and discussions about long-term institutional adoption.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors await critical Phase III clinical data and the upcoming FDA decision for ivonescimab, a potential first-in-class cancer therapy. The community is actively debating the reliability of trial data, the company's valuation against established biotech peers, and the strategic significance of its recent plenary presentation at ASCO.

Canary XRP ETF - Common Shares of Beneficial Interest

Canary XRP ETF

XRP is generating intense market interest as institutional adoption of the XRP Ledger accelerates and ETF inflows continue to show resilient demand. The community is actively discussing the potential impact of regulatory milestones, such as the Clarity Act, on the integration of XRP into global financial infrastructure and real-world asset tokenization.

Volatility Shares Trust - Volatility Shares Trust XRP ETF

XRP ETF

The XRP community is rallying behind the assets deepening institutional integration, driven by record-setting ETF inflows, expanding real-world asset (RWA) tokenization, and critical advancements in U.S. regulatory clarity. Investors are actively discussing the potential for broader banking adoption and the long-term impact of its payment infrastructure, fueling a narrative that XRP is transitioning into a core component of the global financial system.

Samsara, Inc. develops internet connected sensor systems. It combines plug-and-play sensors, wireless connectivity, and cloud-hosted software integrated for deployment. The company was founded by John Bicket and Sanjit Biswas in 2015 and is headquartered in San Francisco, CA.

Samsara Inc - Ordinary Shares - Class A

Samsara Inc

Samsara Inc. (IOT) is currently drawing significant investor interest as the market positions itself ahead of the upcoming Q1 2027 earnings report. The community is actively debating the company's valuation and its unique position in the physical operations sector, with many traders looking for a breakout above $32.50 as a signal of renewed bullish momentum.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

Binance's native token is currently seeing high volatility as traders react to a wave of speculative noise and conflicting market narratives, including ongoing regulatory scrutiny and discussions around potential ETF developments. While some community members are focused on long-term accumulation and the utility of the Binance ecosystem, others are debating the impact of macroeconomic trends and the influx of low-cap meme coins siphoning volume from established digital assets.

Direxion Shares ETF Trust - Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X ETF

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

GUSH is trending as investors aggressively debate the volatility of oil and gas exploration stocks amid ongoing Middle East tensions and speculation over potential supply disruptions at the Strait of Hormuz. While some community members view current price action as a buying opportunity based on geopolitical instability, others are skeptical, citing the risk of rapid reversals should diplomatic solutions or production shifts emerge.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The Global X DAX Germany ETF (DAX) is currently trending as traders and analysts utilize Elliott Wave theory to navigate its bullish recovery, with community discussions focusing on high-frequency 'Blue Box' buying zones and the index's resilience amidst shifting geopolitical trade tensions. Sentiment remains heavily influenced by technical roadmap updates, as members track the index's ability to maintain upward momentum and potential breakout targets.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending as community members rally behind its diverse ecosystem of IRL initiatives, including branded merchandise, spices, and racing projects, which they view as key drivers for long-term growth. Investors are actively discussing the project's organic, builder-focused culture and are frequently sharing their conviction through consistent accumulation as they position for future potential.

Global X Funds - Global X Funds Global X Robotics & Artificial Intelligence ETF

Global X Funds Global X Robotics & Artificial Intelligence ETF

Investors are closely monitoring BOTZ as the ongoing artificial intelligence and robotics boom drives interest in thematic ETFs. Community discussion frequently highlights the fund's exposure to major AI players and the potential for long-term growth as companies increasingly turn to automation to solve supply chain and labor challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IBRX Stock Outlook After Q1 Results and a New FDA Review

ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.

ImmunityBio: Anktiva Explained and What Comes Next

IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.

AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.

How Agenus' Pipeline Progress Unlock Its Next Growth Phase

AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study evaluating botensilimab (BOT), Agenus multifunctional Fc-enhanced anti-CTLA-4 antibody, with balstilimab (BAL), an anti-PD-1 antibody, in patients with...

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new retrospective data showing that Noetiks artificial intelligence-based TARIO-2 model identified spatial tumor microenvironment patterns associated with clinical outcomes from routine pretreatment tumor pathology...

AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?

Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination...

Agenus (AGEN) Q1 Earnings and Revenues Miss Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -51.43% and -73.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus

Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.

This account has been verified as an official AGEN representative.

Verified Account

Agenus Communications

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.06	--	--	N/A
Q1 '26	$2.10	--	--	N/A
Q4 '25	-$1.04	--	--	N/A
Q3 '25	$2.20	$1.94	-11.68%	MISSED
Q2 '25	$2.42	-$1.00	-141.32%	MISSED

AGEN
Agenus Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings

Compact View

Latest AGEN News

AGENAgenus Inc